Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review.

Undurraga J, Baldessarini RJ.

Neuropsychopharmacology. 2012 Mar;37(4):851-64. doi: 10.1038/npp.2011.306. Epub 2011 Dec 14. Review.

2.

Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis.

Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA; Multiple Meta-Analyses of New-Generation Antidepressants (MANGA) Study Group.

CNS Drugs. 2008;22(7):587-602. Review.

PMID:
18547127
3.

Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?

Ioannidis JP.

Philos Ethics Humanit Med. 2008 May 27;3:14. doi: 10.1186/1747-5341-3-14.

4.

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.

Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.

J Clin Psychiatry. 2011 Apr;72(4):464-72. doi: 10.4088/JCP.10m06191. Erratum in: J Clin Psychiatry. 2011 Jun;72(6):874.

PMID:
21527123
5.

Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.

Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI.

J Clin Psychiatry. 2011 Aug;72(8):1144-51. doi: 10.4088/JCP.10m06217. Epub 2011 Apr 19.

PMID:
21536001
6.

Declining efficacy in controlled trials of antidepressants: effects of placebo dropout.

Schalkwijk S, Undurraga J, Tondo L, Baldessarini RJ.

Int J Neuropsychopharmacol. 2014 Aug;17(8):1343-52. doi: 10.1017/S1461145714000224. Epub 2014 Mar 13.

PMID:
24621827
7.

Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.

Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI.

J Clin Psychiatry. 2011 Dec;72(12):1660-8. doi: 10.4088/JCP.10r06531.

PMID:
22244025
8.

Should we treat depression with drugs or psychological interventions? A reply to Ioannidis.

Davis JM, Giakas WJ, Qu J, Prasad P, Leucht S.

Philos Ethics Humanit Med. 2011 May 10;6:8. doi: 10.1186/1747-5341-6-8.

9.

Newer generation antidepressants for depressive disorders in children and adolescents.

Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD004851. doi: 10.1002/14651858.CD004851.pub3. Review.

PMID:
23152227
10.

Duloxetine versus other anti-depressive agents for depression.

Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD006533. doi: 10.1002/14651858.CD006533.pub2. Review.

11.

A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder.

Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M.

J Clin Psychopharmacol. 2006 Feb;26(1):56-60.

PMID:
16415707
12.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
13.

Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.

Maneeton N, Maneeton B, Srisurapanont M, Martin SD.

BMC Psychiatry. 2012 Sep 27;12:160. doi: 10.1186/1471-244X-12-160.

14.

Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants.

Bauer M, Adli M, Bschor T, Pilhatsch M, Pfennig A, Sasse J, Schmid R, Lewitzka U.

Neuropsychobiology. 2010;62(1):36-42. doi: 10.1159/000314308. Epub 2010 May 7. Review.

15.

Amitriptyline versus placebo for major depressive disorder.

Leucht C, Huhn M, Leucht S.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD009138. doi: 10.1002/14651858.CD009138.pub2. Review.

PMID:
23235671
16.

Milnacipran versus other antidepressive agents for depression.

Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006529. doi: 10.1002/14651858.CD006529.pub2. Review.

17.

[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].

Gourion D.

Encephale. 2008 Jan;34(1):73-81. doi: 10.1016/j.encep.2007.12.001. Epub 2008 Feb 5. Review. French.

PMID:
18514154
18.

Solving the antidepressant efficacy question: effect sizes in major depressive disorder.

Vöhringer PA, Ghaemi SN.

Clin Ther. 2011 Dec;33(12):B49-61. doi: 10.1016/j.clinthera.2011.11.019. Epub 2011 Dec 2. Review.

19.

Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.

Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI.

J Clin Psychiatry. 2010 Jun;71(6):682-8. doi: 10.4088/JCP.10r05976blu.

PMID:
20573327
20.

Role of lithium augmentation in the management of major depressive disorder.

Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M.

CNS Drugs. 2014 Apr;28(4):331-42. doi: 10.1007/s40263-014-0152-8. Review.

PMID:
24590663
Items per page

Supplemental Content

Write to the Help Desk